PDA

View Full Version : Articles of Interest

Pages : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 [15] 16 17 18
  1. Cabozantinib (MET and VEGFR2 inhibitor)
  2. NeuVax vaccine
  3. NKTR-102 topoisomerase I-inhibitor
  4. A new stink over breast cancer fundraising, lawsuits, and perfume
  5. Ports defective
  6. Telomerase Expression, Telomere Length, BC adj tx & outcomes
  7. ImmunoCellular therapeutics ICT-107 (multitarget immuno)
  8. Crucial Molecule Involved In Spread Of Breast Cancer
  9. A four-dimensional view of breast cancer treatment
  10. Xeloda failed? Even small change in schedule can make it work.
  11. Beta Blockers: blocking cancer?
  12. Anaplastic lymphoma kinase in BC (Crizotinib et al)
  13. Estrogen signaling...
  14. Dual IHS Test Approved by FDA
  15. With lofty goals, drug makers face a long and costly journey (Cyclopamine to IPI-926)
  16. category "Huh?"
  17. Basal and Luminal features in Her2 breast cancer
  18. Excercise/activity
  19. Male breast cancer
  20. ASBS: Prophylactic Mastectomy Good Even Years Later
  21. Everolimus ("Afinitor")
  22. Tetrathiomolybdate (copper chelator/reducer)
  23. Clioquinol (antibiotic, chelator)
  24. Prognostic factors & molecular subtype in very young bc patients
  25. CTCs as prognostic and predictive factors for mbc treatments
  26. Early Chemical Exposures May Affect Breast Health
  27. Elevated pre-treatment levels of plasma C-reactive protein associated w/bc outcomes
  28. Reputation and Precedent in the Bevacizumab Decision
  29. Changing End Points in Breast-Cancer Drug Approval — The Avastin Story
  30. Gene signature for endocrine resistance studied
  31. National Directory for Comparing Health Care Quality
  32. Managed Care Enters Exam Room...
  33. Cancer Info source - NCI
  34. Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose
  35. Vitamin D Supplementation Prevents Breast Cancer Therapy-Related Bone Loss
  36. Drug Combination (Tykerb+Rapamycin) for Triple-Negative Breast Cancers
  37. Effect of Very Small Tumor Size on Cancer-Specific Mortality in Node-Positive BC
  38. Ovarian suppression before and during chemo reduces early menopause
  39. New Anti-Cancer Agent Developed for HER2+ BC Shows Promise in Pre-Clinical Studies
  40. The future of cancer lies behind us
  41. Uncertainty Rules Adjuvant Chemo for Early HER2 Breast Cancer
  42. TNF-Alpha Activity Eyed for Role in 'Chemo Brain'
  43. Genetic Marker Predicts Taxane-Induced Neuropathy
  44. Dr. Clifford Hudis: The Obesity–Breast Cancer Link
  45. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of Erb
  46. Breaching the Gates of Troy: Drug Delivery Systems for the Central Nervous System
  47. BC biological subtypes predict for sites for distant mets
  48. Bisphosphonate Cancer Risk Divides FDA Officials
  49. Reirradiation of Brain Metastases With Radiosurgery
  50. New Nomograms Predict Lymphedema After Axillary Lymph Node Dissection
  51. Cabozatanib
  52. Evolution hints at a superbug strategy
  53. Adjuvant Trastuzumab Reduces Locoregional Recurrence in Stage 1 BC patients
  54. Alternating Mammos & MRIs effective in BRCA+
  55. Long-Term Risk of Colorectal Cancer After Negative Colonoscopy
  56. Becoming Mindful Of Medical Decision Making
  57. Score Predicts Late Recurrence in ER-Positive Breast Cancer
  58. Chemo Timing Does Not Affect Breast Cancer Recurrence
  59. Taxane-Induced Neuropathy Gives No Clue to Breast Cancer Outcomes
  60. Denosumab Approved for Bone Loss From Hormone Ablation Therapy
  61. U.S. Drug Shortage Could Threaten U.S. Health System
  62. Durable Complete Remission
  63. 10-year-old's research on chemo brain
  64. ESRA expression predicts tamoxifen benefit in bc
  65. Why Doctors Order So Many Tests
  66. Adjuvant Therapy With Zoledronic Acid May Benefit BC Patients Postmenopausal > 5 yrs
  67. Tamoxifen/metabolic study results (early stage bc)
  68. Evidence-Based Medicine
  69. "Breast cancer myths"
  70. Prone Position During Breast Irradiation Lessens Lung Cancer Risk
  71. Male Breast Cancer - Survival Rates
  72. Small molecules can starve cancer cells
  73. Early Detection and Overall Survival
  74. Researchers Examine BPA And Breast Cancer Link
  75. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online
  76. Helping Patients Decide: Ten Steps to Better Risk Communication
  77. halozyme: injection Herceptin
  78. Gene Causing Opposite Effects in Prostate and Breast Cancers Discovered (Androgen)
  79. Non-dense mammographic area and risk of breast cancer
  80. combined influence of multiple sex & growth hormones on bc risk
  81. Study on trauman pts response & inflammation
  82. Could Aspirin be a Viable Adjuvant Treatment for Cancer?
  83. "What do you mean, mammography didn't save my life?"
  84. Regorafenib (oral multikinase inhibitor)
  85. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contral
  86. Results of BCIRG-006 Study
  87. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment.
  88. Obama Administration Takes Action to Reduce Prescription Drug Shortages, Fight Price
  89. Nelfinavir: available Anti HIV, anti cancer
  90. Embryonic signal drives pancreatic cancer and offers a way to kill it
  91. Dasatinib (Sprycel)
  92. The Shortage of Essential Chemotherapy Drugs in the United States
  93. Routine Quality Cancer Care Must Integrate Psychosocial Assessment
  94. CTCs as pharmacodynamic as biomarker in early clinical oncological trials
  95. ASCO Pushes for Cancer Trial Improvements
  96. Effective Risk Communication to Cancer Patients
  97. still no understanding why?
  98. Halting the spread...
  99. Fda
  100. Breast Cancer Genetic Profiling Has Not Achieved Personalized Medicine Yet
  101. ‘Cancer’ or ‘Weird Cells’: Which Sounds Deadlier?
  102. Skin Tumors Induced by Sorafenib
  103. Her 2/Her 3 article - I just found this, repost?
  104. Drug Shortages — A Critical Challenge for the Generic-Drug Market
  105. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
  106. Somatic allelic imbalances in Her2+ bc
  107. Stress and breast cancer: from epidemiology to molecular biology
  108. FDA Clears Dako's Companion Dx for Herceptin
  109. Patients Want To Read Doctors' Notes, But Many Doctors Balk
  110. 30K French Women Recieve Faulty implants
  111. T-DM1 Supports QOL in HER2+ Metastatic Breast Cancer
  112. Vitamin D Deficiency/Breast Cancer Link Questioned
  113. Oncotype DX Cost Effective, Challenges Breast Cancer Practice
  114. Researchers successfully treat previously lethal doses of radiation
  115. The Immortal Life of HEnrietta LAcks--a must read
  116. Sono-Photo Dynamic Therapy (SPDT)
  117. Imaging/measurement issues
  118. Review of Current Standard of Care for Neoadjuvant Her2+ BC treatment
  119. Recommendations Proposed for Off-Label Cancer Treatments
  120. Camp LeJeune & Male Breast Cancer`
  121. Must read: Aloe vera and natural cures/healing
  122. Dr. Clifford Hudis: 2011 Top Stories in Breast Cancer
  123. Microarray-based gene expression profiling for bc classification, prognostication,
  124. US Oncologists Confront Pressure to Curb Cancer Costs
  125. Komen pulls screening grants from Planned Parenthood
  126. The Cancer Drugs Fund (England)
  127. Winter adds to ordeal of cancer patients
  128. Patients and Doctors — The Evolution of a Relationship
  129. Molecular Breast Imaging Is Superior to Ultrasound and Mammography for the Detection
  130. Foreign Shipments to Ease Shortage of 2 Cancer Drugs
  131. Rigosertib
  132. Breast Cancer and the Environment Report offers research roadmap
  133. Loss of Her2+ in Metastatic Sites of Her2+ BC
  134. 14th International Symposium on Anti-Angiogenic Agents
  135. Use of estrogen alone
  136. Intratumor Heterogeneity and Branched Evolution
  137. Nature | News Biopsy gives only a snapshot of tumour diversity
  138. Estrogen Protects Against Breast Cancer Long After Treatment
  139. Research on genetic reasons for AI muscular-skeleton SE's
  140. ER and HER2 expression are positively correlated in HER2 neg bc
  141. Lymphedema: Separating Fact From Fiction
  142. Endpoints Explained—Part I
  143. Breast Cancer and the Environment
  144. What Affects Long-Term Breast Cancer Recurrence Risk?
  145. Shame it is always about money :(
  146. Single antibody shrinks variety of human tumors
  147. Roche to file T-DM1 breast cancer drug on good data
  148. Tool
  149. 'Targeted therapies' from Breastcancer.org
  150. Scientists Identify 10 Different Types of Breast Cancer
  151. 103rd Annual American Association of Cancer Research (AACR) Meeting
  152. The White Adipose Tissue Used in LipotransferIs a Rich Reservoir of CD34+ Progenitors
  153. Cold comfort in quest for cancer cure
  154. Definition & Impact of PCR on Prognosis After Neoadjuvant Chemo in Various BC Types
  155. Tooth extraction in patients on zoledronic acid therapy
  156. Etoposide/VP-16
  157. Biomarkers Characterization of Circulating Tumour Cells in Breast Cancer Patients
  158. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell
  159. Antiangiogenic Therapy In Breast Cancer—What We Know and What We Don't
  160. BIND-014 (Nano Accurin with Taxotere)
  161. Magnets against cancer
  162. back to the future in MBC
  163. The microenvironment in breast cancer progression
  164. Targeted agents to reverse resistance to endocrine therapy in mbc -Where are we now
  165. Breasts: A Natural and Unnatural History
  166. Docs Need Primer on Long-Term Effects of Chemotherapy
  167. NCI Article on Understanding Screening Stats
  168. Andrographolide
  169. Defeating Herceptin Resistance
  170. Targeting breast cancer vaccines to dendritic cells (for Her2+ bc)
  171. FDA Breast Cancer Guidance Paves Way for Accelerated Approval With One Trial
  172. Tykerb/Herceptin Combination Will Go Before FDA Advisory Panel
  173. Expert commentary on recent T-DM1 Trials
  174. BRCA Genes Cause Increased Fertility
  175. Propranolol (beta blocker)
  176. ‘Super Herceptin’ Excels in HER2 Breast Cancer
  177. Her2+ PR+ bc patients may benefit from anti-progestin therapy
  178. Petition
  179. Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
  180. Dental Plaque and Cancer outcomes - related?
  181. Diabetes, Metformin, and Breast Cancer in Postmenopausal Women
  182. Do Pregnacy Associated Breast Cancers Differ from other bc's in Young Women?
  183. Scalp Cooling Protects Against Chemotherapy-Induced Alopecia
  184. The evolving landscape of protein kinases in breast cancer: Clinical implications
  185. Cents and Sensitivity — Teaching Physicians to Think about Costs
  186. Evidence mounts that a single antibody could knock out many cancers
  187. Features of cancer management in obese patients
  188. Brain Mets in Breast Cancer: Breaking Through the Barrier
  189. Menopausal status and choosing therapies
  190. Dense Breasts
  191. Breast density predicts endocrine treatment outcome in the adjuvant setting
  192. The Natural History of Hormone Receptor–Positive Breast Cancer
  193. Conversion of Her2+ and hormone receptor in bc mets to the brain
  194. Subcutaneous Versus Intravenous Administration of (Neo)Adjuvant Trastuzumab
  195. Missing Gene May Drive More Than One in Four Breast Cancers
  196. Is breast cancer a part of Lynch syndrome?
  197. Increased risk for endometrial cancer
  198. Transparency for Clinical Trials — The TEST Act
  199. Evidence Mounts on Heart Failure After Trastuzumab in Breast Cancer Survivors
  200. Plea to FDA: Set Realistic Bar for New Breast Cancer Trial Endpoint
  201. A Possible Therapy For Tamoxifen-Resistant Breast Cancer Identified
  202. Far From ‘Junk,’ DNA Dark Matter Plays Crucial Role
  203. Cardiotoxicity in Cancer Patients: Often More Malignant Than Cancer—Part 1
  204. Cardiotoxicity in Cancer Patients: Often More Malignant Than Cancer—Part 2
  205. There Is More to Life Than Death
  206. Breast Cancer After Hodgkin's Lymphoma
  207. hair
  208. Brazilian keratin?
  209. Pot is good for you!
  210. New info
  211. Comprehensive molecular portraits of human breast tumours
  212. One odd tumor case may yield clues to help millions
  213. Approach to Endocrine Therapy in Breast Cancer—Part II
  214. Approach to Endocrine Therapy in Breast Cancer—Part I
  215. Impact of Hormone receptor status on recurrence in HER2+ bc
  216. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
  217. Association between common risk factors and molecular subtypes in breast cancer
  218. Treating HER2+ Breast Cancer With HIV Drug
  219. rospective Study to Assess Fluid Accumulation and Tenosynovial Changes in AI users
  220. Can Lapatinib Prevent Brain Metastases from Breast Cancer? Data 'Inconclusive'
  221. Estimating chemotherapy effects for metastatic cancers
  222. Gene Patents may be the new obstacle to our cure . . .
  223. Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant BC
  224. Cardiac Toxicity Not Seen 25 Years after Breast Radiation
  225. Statin Use and Reduced Cancer-Related Mortality
  226. Memantine Protects Cognitive Function After Whole Brain Irradiation
  227. Migratory gene expression signature predicts poor patient outcome: Are cancer stem
  228. Extended adjuvant endocrine therapy in hormone dependent breast cancer
  229. Long-Term Effects of Chemo on the Cognitive Function of Cancer Patients
  230. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence
  231. Most Medicare Patients Wait Weeks Before Breast Cancer Surgery
  232. Increasing Fulvestrant Dose in Advanced ER-Positive Breast Cancer
  233. Neoadjuvant Chemo May Benefit Young Breast Cancer Patients More
  234. Surviving Breast Cancer Shouldn't Mean Relinquishing Intimacy
  235. Patient Expectations About Their Cancer Treatment
  236. Is the Cure for Cancer Inside You?
  237. Genes Predict Adjuvant Trastuzumab Outcomes in HER2-Positive Breast Cancer
  238. Review of radiation options for early stage bc
  239. A Call to Eliminate 'Chemotherapy Concession'
  240. How Relevant is Hormone Receptor Status to Her2+ bc outcomes?
  241. Interesting Presentation on Vitamin D
  242. Work stress and risk of cancer
  243. Patient-Specific Cancer Cell Lines Designed To Predict Chemotherapy Sensitivity
  244. Dishing out cancer treatment
  245. Cancer Rehab Begins To Bridge A Gap To Reach Patients
  246. New Drug for Vaginal Atrophy
  247. New Score Helps Predict Late Distant Metastases in ER+ HER2- Breast Cancer
  248. Metabolic Syndrome Skews Oncotype DX Reliability
  249. New Tool Predicts Late Recurrence in Breast Cancer
  250. Estrogen Testing